Cardiovascular events in patients with COPD after long-acting bronchodilator initiation

ERJ Open Research 2026 Open access

Read full text
Authors: Dave Singh, Ana R. Sousa, David E. Newby, Michele Jönsson Funk, Miguel Román-Rodríguez, Péter Kardos, Gema Requena, Alison Donald, David Slade, Chris H. Compton
DOI: 10.1183/23120541.01691-2025
Cited by: 0
References: 33

Abstract

Background Real-world evidence concerning the cardiovascular (CV) risk of umeclidinium (UMEC) monotherapy or UMEC/vilanterol (VI) is scarce. This real-world study investigated CV risk in new users of UMEC or UMEC/VI versus new users of tiotropium (TIO) in patients with chronic obstructive pulmonary disease (COPD). Methods This prospective, observational, multinational, cohort study enrolled patients ≥18 years with COPD who initiated UMEC, UMEC/VI or TIO between 2 February 2016 and 31 January 2023. Noninferiority (95% confidence interval upper bound

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Inhalation and Respiratory Drug Delivery Asthma and respiratory diseases

Publication details

Journal / source
ERJ Open Research
Volume
12
Issue
3
Pages
01691–2025
Publication date
16 February 2026
Language
EN